In this cross-sectionnal study the aim is to increase the understanding of posterior staphyloma through a unique European consortium. Therefore, all eligible patients that either visit the outpatient clinic at Radboud in Nimegen, the Netherlands, or visit University Hopital Puerta de HierroMajadahonda in Madrid, Spain, or visit University Hospital Cochin in Paris, France, and after consenting, will be included.
600 high myopic European cases are expecting. A standardized protocol in all centers in order to create a uniform dataset.
Besides the standard of care, blood samples will be collected.
All data collected will be stored in an onlie Castor database
Adults with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with and without posterior staphyloma
Adults aged 18 years or over
Patient with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with good quality retinal imaging
Patient who has signed a consent form to participate in the study
Any systemic or ocular pathologies with an impact on the posterior segment of the eye
Diabetes
Systemic inflammatory disease: sarcoidosis, rheumatoid arthritis, systemic lupus erythematosus, Horton's disease
Patients with retinitis pigmentosa
Parallel
blood sampling for DNA
Biological/VaccineBlood sampling for DNA and serum and plasma colection and PBMC
Differential gene expression between myopic patients with and without staphyloma
Genetic analysis
Establish correlations between the phenotype and systemic molecular markers
Proteomic analysis in blood
Compare phenotype of staphyloma between France and 2 other European countries: Netherlands and Spain
Retinal imaging
Click on the lead sponsor to view all of their trials.
Assistance Publique - Hôpitaux de Paris
Lead sponsor
URC-CIC Paris Descartes Necker Cochin
Collaborator
